Zilebesiran Phase 2 Results Show Long-Lasting Blood Pressure

Product Description

Zilebesiran’s path towards becoming the first long-lasting antihypertensive medication gained more momentum, with new topline Phase 2 results demonstrating that a single injection significantly reduces systolic blood pressure through six months.

In Alnylam's Search For A Mass-Market Treatment, A Twice Yearly Blood Pressure Injection Could Fit The Bill :: Scrip

Innovative Treatment for Hypertension: One Shot Every Quarter or Even Six Months • BioPharma Media

Novel antihypertensive agents for resistant hypertension: what does the future hold?

Can siRNA Improve Compliance in Patients With Hypertension?

Treatment for Mild Chronic Hypertension during Pregnancy

Single dose of zilebesiran safely and effectively lowered blood pressure for six months

Zilebesiran Phase 2 Results Show Long-Lasting Blood Pressure Impact - Cardiac Wire

Ben Ansell (@DrBenAnsell) / X

PDF) Abstract 14387: Dose-Related Reductions in Blood Pressure With a RNA Interference (RNAi) Therapeutic Targeting Angiotensinogen in Hypertensive Patients: Interim Results From a First-In-Human Phase 1 Study of ALN-AGT01

Roche's bet pays off as Alnylam hypertension med hits in phase 2

Zilebesiran's Long-Lasting Antihypertensive Potential - Cardiac Wire

Roche to co-develop hypertension RNAi therapeutic